| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
775 Stock Overview
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, markets, and sells health and agriculture-related products in the Asia Pacific and North America.
CK Life Sciences Int'l., (Holdings) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.79 |
| 52 Week High | HK$1.28 |
| 52 Week Low | HK$0.56 |
| Beta | 0.55 |
| 1 Month Change | 19.70% |
| 3 Month Change | 11.27% |
| 1 Year Change | 5.33% |
| 3 Year Change | 0% |
| 5 Year Change | 33.90% |
| Change since IPO | -63.26% |
Recent News & Updates
Recent updates
Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly
Sep 27
Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?
Sep 16Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)
Aug 21These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively
Apr 14CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry
Mar 18If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns
Feb 01
What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?
Jan 04CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet
Dec 09We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide
Nov 18Shareholder Returns
| 775 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 14.5% | 5.2% | 3.0% |
| 1Y | 5.3% | -44.8% | -20.1% |
Return vs Industry: 775 exceeded the Hong Kong Biotechs industry which returned -44.8% over the past year.
Return vs Market: 775 exceeded the Hong Kong Market which returned -20.1% over the past year.
Price Volatility
| 775 volatility | |
|---|---|
| 775 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 775 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 775's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,829 | Alan Abel Yu | https://www.ck-lifesciences.com |
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, markets, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines. The company is also involved in the contract manufacturing of complementary healthcare medicines, pharmaceutical products, and cosmetics; licensing of registration activities and the importation of finished agricultural goods; holding of land and buildings; financing activities; investment in financial instruments and vineyards; trading of biotechnology products and nutritional supplements; and manufacturing, wholesaling, retailing, and distribution of nutraceutical products.
CK Life Sciences Int'l., (Holdings) Inc. Fundamentals Summary
| 775 fundamental statistics | |
|---|---|
| Market Cap | HK$7.59b |
| Earnings (TTM) | HK$127.53m |
| Revenue (TTM) | HK$5.30b |
59.6x
P/E Ratio1.4x
P/S RatioIs 775 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 775 income statement (TTM) | |
|---|---|
| Revenue | HK$5.30b |
| Cost of Revenue | HK$3.72b |
| Gross Profit | HK$1.59b |
| Other Expenses | HK$1.46b |
| Earnings | HK$127.53m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.013 |
| Gross Margin | 29.96% |
| Net Profit Margin | 2.40% |
| Debt/Equity Ratio | 130.9% |
How did 775 perform over the long term?
See historical performance and comparison